Cargando…

Immune-Related RNA-Binding Protein-Based Signature With Predictive and Prognostic Implications in Patients With Lung Adenocarcinoma

Background: Dysregulation of RNA-binding proteins (RBPs) in cancers is associated with immune and cancer development. Here, we aimed to profile immune-related RBPs in lung adenocarcinoma (LUAD) and construct an immune-related RBP signature (IRBPS) to predict the survival and response to immunotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Lei, Li, Wanru, Yang, Ting, Hu, Siqi, Zou, Qiong, Jiao, Ju, Jiang, Ningyi, Zhang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136055/
https://www.ncbi.nlm.nih.gov/pubmed/35647031
http://dx.doi.org/10.3389/fmolb.2022.807622
_version_ 1784714092289720320
author Xu, Lei
Li, Wanru
Yang, Ting
Hu, Siqi
Zou, Qiong
Jiao, Ju
Jiang, Ningyi
Zhang, Yong
author_facet Xu, Lei
Li, Wanru
Yang, Ting
Hu, Siqi
Zou, Qiong
Jiao, Ju
Jiang, Ningyi
Zhang, Yong
author_sort Xu, Lei
collection PubMed
description Background: Dysregulation of RNA-binding proteins (RBPs) in cancers is associated with immune and cancer development. Here, we aimed to profile immune-related RBPs in lung adenocarcinoma (LUAD) and construct an immune-related RBP signature (IRBPS) to predict the survival and response to immunotherapy. Methods: A correlation analysis was performed to establish a co-expression network of RBPs and immune-related genes (IRGs) to characterize immune-related RBPs in the TCGA–LUAD cohort (n = 497 cases). Then, a combination of the Random survival forest (RSF) and Cox regression analysis was performed to screen the RBPs and establish IRBPS. This was followed by independent validation of IRBPS in GSE72094 (n = 398 cases), GSE31210, (n = 226 cases), and GSE26939 (n = 114 cases). Differences between the low- and high-risk groups were compared in terms of gene mutations, tumor mutation burden, tumor-infiltrating lymphocytes, and biomarkers responsive to immunotherapy. Results: DDX56, CTSL, ZC3H12D, and PSMC5 were selected and used to construct IRBPS. The high-risk scores of patients had a significantly worse prognosis in both training and testing cohorts (p < 0.0001 and p < 0.05, respectively), and they tended to be older and have an advanced TNM stage. Furthermore, IRBPS was a prognostic factor independent of age, gender, smoking history, TNM stage, and EGFR mutation status (p = 0.002). In addition, high-risk scores of IRBPS were significantly correlated with tumor-infiltrating lymphocytes (p < 0.05). They also had a high level of PD-L1 protein expression (p < 0.01), number of neoantigens (p < 0.001), and TMB (p < 0.001), implying the possible prediction of IRBPS in the immunotherapy of LUAD. Conclusion: The currently established IRBPS encompassing immune-related RBPs might serve as a promising tool to predict survival, reflect the immune microenvironment, and predict the efficacy of immunotherapy among LUAD patients.
format Online
Article
Text
id pubmed-9136055
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91360552022-05-28 Immune-Related RNA-Binding Protein-Based Signature With Predictive and Prognostic Implications in Patients With Lung Adenocarcinoma Xu, Lei Li, Wanru Yang, Ting Hu, Siqi Zou, Qiong Jiao, Ju Jiang, Ningyi Zhang, Yong Front Mol Biosci Molecular Biosciences Background: Dysregulation of RNA-binding proteins (RBPs) in cancers is associated with immune and cancer development. Here, we aimed to profile immune-related RBPs in lung adenocarcinoma (LUAD) and construct an immune-related RBP signature (IRBPS) to predict the survival and response to immunotherapy. Methods: A correlation analysis was performed to establish a co-expression network of RBPs and immune-related genes (IRGs) to characterize immune-related RBPs in the TCGA–LUAD cohort (n = 497 cases). Then, a combination of the Random survival forest (RSF) and Cox regression analysis was performed to screen the RBPs and establish IRBPS. This was followed by independent validation of IRBPS in GSE72094 (n = 398 cases), GSE31210, (n = 226 cases), and GSE26939 (n = 114 cases). Differences between the low- and high-risk groups were compared in terms of gene mutations, tumor mutation burden, tumor-infiltrating lymphocytes, and biomarkers responsive to immunotherapy. Results: DDX56, CTSL, ZC3H12D, and PSMC5 were selected and used to construct IRBPS. The high-risk scores of patients had a significantly worse prognosis in both training and testing cohorts (p < 0.0001 and p < 0.05, respectively), and they tended to be older and have an advanced TNM stage. Furthermore, IRBPS was a prognostic factor independent of age, gender, smoking history, TNM stage, and EGFR mutation status (p = 0.002). In addition, high-risk scores of IRBPS were significantly correlated with tumor-infiltrating lymphocytes (p < 0.05). They also had a high level of PD-L1 protein expression (p < 0.01), number of neoantigens (p < 0.001), and TMB (p < 0.001), implying the possible prediction of IRBPS in the immunotherapy of LUAD. Conclusion: The currently established IRBPS encompassing immune-related RBPs might serve as a promising tool to predict survival, reflect the immune microenvironment, and predict the efficacy of immunotherapy among LUAD patients. Frontiers Media S.A. 2022-05-13 /pmc/articles/PMC9136055/ /pubmed/35647031 http://dx.doi.org/10.3389/fmolb.2022.807622 Text en Copyright © 2022 Xu, Li, Yang, Hu, Zou, Jiao, Jiang and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Xu, Lei
Li, Wanru
Yang, Ting
Hu, Siqi
Zou, Qiong
Jiao, Ju
Jiang, Ningyi
Zhang, Yong
Immune-Related RNA-Binding Protein-Based Signature With Predictive and Prognostic Implications in Patients With Lung Adenocarcinoma
title Immune-Related RNA-Binding Protein-Based Signature With Predictive and Prognostic Implications in Patients With Lung Adenocarcinoma
title_full Immune-Related RNA-Binding Protein-Based Signature With Predictive and Prognostic Implications in Patients With Lung Adenocarcinoma
title_fullStr Immune-Related RNA-Binding Protein-Based Signature With Predictive and Prognostic Implications in Patients With Lung Adenocarcinoma
title_full_unstemmed Immune-Related RNA-Binding Protein-Based Signature With Predictive and Prognostic Implications in Patients With Lung Adenocarcinoma
title_short Immune-Related RNA-Binding Protein-Based Signature With Predictive and Prognostic Implications in Patients With Lung Adenocarcinoma
title_sort immune-related rna-binding protein-based signature with predictive and prognostic implications in patients with lung adenocarcinoma
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136055/
https://www.ncbi.nlm.nih.gov/pubmed/35647031
http://dx.doi.org/10.3389/fmolb.2022.807622
work_keys_str_mv AT xulei immunerelatedrnabindingproteinbasedsignaturewithpredictiveandprognosticimplicationsinpatientswithlungadenocarcinoma
AT liwanru immunerelatedrnabindingproteinbasedsignaturewithpredictiveandprognosticimplicationsinpatientswithlungadenocarcinoma
AT yangting immunerelatedrnabindingproteinbasedsignaturewithpredictiveandprognosticimplicationsinpatientswithlungadenocarcinoma
AT husiqi immunerelatedrnabindingproteinbasedsignaturewithpredictiveandprognosticimplicationsinpatientswithlungadenocarcinoma
AT zouqiong immunerelatedrnabindingproteinbasedsignaturewithpredictiveandprognosticimplicationsinpatientswithlungadenocarcinoma
AT jiaoju immunerelatedrnabindingproteinbasedsignaturewithpredictiveandprognosticimplicationsinpatientswithlungadenocarcinoma
AT jiangningyi immunerelatedrnabindingproteinbasedsignaturewithpredictiveandprognosticimplicationsinpatientswithlungadenocarcinoma
AT zhangyong immunerelatedrnabindingproteinbasedsignaturewithpredictiveandprognosticimplicationsinpatientswithlungadenocarcinoma